Vera Therapeutics, Inc. 4

Fordyce Marshall, President and CEO of Vera Therapeutics, Inc., exercised 46,250 stock options at $2.8968 and sold 46,250 Class A Common shares on July 7, 2026 for roughly $1.95 million in total proceeds under a Rule 10b5-1 plan.

On July 7, 2026, Vera Therapeutics, Inc. President and CEO Fordyce Marshall exercised 46,250 stock options at an exercise price of $2.8968 per share, acquiring an equal number of Class A Common shares, and then sold an aggregate 46,250 shares in multiple open-market transactions under a Rule 10b5-1 trading plan at weighted-average prices ranging from approximately $40.78 to $43.59 per share. The transactions effectively represent a cashless exercise and sale, with gross sale proceeds of roughly $1.95 million versus an exercise cost of about $134,000, while his directly held beneficial ownership decreased to 235,244–281,494 shares as reflected across the different rows and was corrected by this amended Form 4 to report the proper post-transaction holdings. The amendment clarifies the inclusion of the option exercise and corrects the amounts of securities beneficially owned following the reported transactions, and notes that sales were executed in multiple price tranches, with full breakdowns available upon request.

Filing Facts

CIK

1831828

Ticker

VERA

Form

4

Source Type

fda

Accession

0001859453-26-000013

Alert Tier

7